Vaxart Stock Discussion

$Vaxart (VXRT.US)$
Analyst writes that Vaxart's oral tablet could offer better immunity than traditional intramuscular vaccines, which have faced challenges.
Oppenheimer initiated with an Outperform rating and a price target of $4, representing significant potential upside.
“VXRT is uniquely positioned as a leading company developing oral vaccines against COVID-19, supported by one of the largest BARDA-funded Project NextGen Awards,” the analyst writes.
“We think oral vaccines hold unique proper...

$Vaxart (VXRT.US)$
After hours, we can see this going to $1.05 and possibly $1.15

$Vaxart (VXRT.US)$
can see $1.15 coming

$Vaxart (VXRT.US)$
direct hit 🎯 $1.0

$Vaxart (VXRT.US)$
time to fly, looking for $1

$Vaxart (VXRT.US)$
Vaxart, Inc. (NASDAQ: VXRT) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. BARDA awarded Vaxart up to $453 million for a Phase 2b trial of its oral COVID-19 vaccine.
2. The company plans to initiate the 10,000-subject Phase 2b trial in H2 2024, pending FDA alignment.
3. Vaxart is in discussions with the FDA regarding norovirus vaccine data and potential next steps.
4. Q2 2024 financial results: $62.6 million in cash and inv...

$Vaxart (VXRT.US)$
Wow Earnings Killer  1517 % !!!

$Vaxart (VXRT.US)$ time to buy

$Vaxart (VXRT.US)$
Show me your power!
hold for few days, finally...